Ramsay Générale de Santé SA (GDS) Fair Value & Analysis
Healthcare · FR · Market cap €1.3B
Fair value as of: Jun 25, 2026
From 16 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from €46.69 to €45.14 (−3.3%) since Jun 24, 2026. Share price −0.9% over the past month.
Price vs Fair Value (12 months)
12‑month range €8.61 – €11.25 · fair‑value band €25.44 – €64.85 · the €11.15 price screens below the €45.14 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Ramsay Générale de Santé SA (GDS) currently trades at €11.15, while our model-based Fair Value estimate is €45.14 — implying the stock looks roughly 304.8% undervalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Ramsay Générale de Santé SA generated revenue of €5.4B at a net margin of -0.5%. Revenue grew 2.7% year over year. It earns a return on equity of -2.2%. Net debt stands at €3.7B. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Ramsay Générale de Santé SA operates healthcare facilities in France, Sweden, Norway, Denmark, and Italy. The company operates medical centres, and mental health day care centres in France; and provides primary medicine, medicine surgery obstetrics (MSO) dialysis, oncology, medical imaging, medical care, follow-up and rehabilitation care, geriatrics, home care and hospitalization, mental health care, and addiction treatment, telemedicine e health, elderly, emergency, maternity, nutrition, obesity and eating disorders, outpatient surgery and eras, relaxation therapy, cardiac and neuro surgery, clinical and biological activities in medically assisted reproduction, cancer treatment for external radiotherapy and brachytherapy, and SMR services. The company was formerly known as Générale de Santé SA and changed its name to Ramsay Générale de Santé SA in December 2015. The company was founded in 1987 and is headquartered in Paris, France. Ramsay Générale de Santé SA operates as a subsidia…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ramsay Générale de Santé SA reported revenue of €5.2B in FY2025 versus €4.0B in FY2021, a compound +6.8%/yr. Reported net income was −€54.1M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.47 | $8.55 | -25% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.17 | -32% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.76 | R$30.33 | -7% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ramsay Générale de Santé SA (GDS) undervalued?
What is the fair value of GDS?
What is the quality score of GDS?
What is the revenue of Ramsay Générale de Santé SA (GDS)?
What is the net profit margin of GDS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.